Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,567 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.
DiNardo CD, Olin R, Wang ES, Skikne B, Rosenthal J, Kumar P, Sumi H, Hizukuri Y, Hong Y, Patel P, Seki T, Duan T, Lesegretain A, Andreeff M. DiNardo CD, et al. Among authors: seki t. Cancer Med. 2024 Jul;13(14):e70028. doi: 10.1002/cam4.70028. Cancer Med. 2024. PMID: 39030997 Free PMC article. Clinical Trial.
Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.
Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Zhao R, Heese L, Ma W, Ma MCJ, DiNardo C, Pierce S, Patel KP, Tse A, Davis RE, Rao A, Andreeff M. Ishizawa J, et al. Among authors: seki t. Cancer Res. 2018 May 15;78(10):2721-2731. doi: 10.1158/0008-5472.CAN-17-0949. Epub 2018 Feb 28. Cancer Res. 2018. PMID: 29490944 Free PMC article.
Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias.
Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA, Khazaei S, Mak PY, Tao W, Carter BZ, Boettcher S, Ebert BL, Daver NG, Konopleva M, Seki T, Kojima K, Andreeff M. Nishida Y, et al. Among authors: seki t. Sci Adv. 2023 Dec;9(48):eadh1436. doi: 10.1126/sciadv.adh1436. Epub 2023 Nov 29. Sci Adv. 2023. PMID: 38019903 Free PMC article.
Synthesis and evaluation of novel orally active p53-MDM2 interaction inhibitors.
Miyazaki M, Naito H, Sugimoto Y, Yoshida K, Kawato H, Okayama T, Shimizu H, Miyazaki M, Kitagawa M, Seki T, Fukutake S, Shiose Y, Aonuma M, Soga T. Miyazaki M, et al. Among authors: seki t. Bioorg Med Chem. 2013 Jul 15;21(14):4319-31. doi: 10.1016/j.bmc.2013.04.056. Epub 2013 Apr 30. Bioorg Med Chem. 2013. PMID: 23685175
Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships.
Miyazaki M, Kawato H, Naito H, Ikeda M, Miyazaki M, Kitagawa M, Seki T, Fukutake S, Aonuma M, Soga T. Miyazaki M, et al. Among authors: seki t. Bioorg Med Chem Lett. 2012 Oct 15;22(20):6338-42. doi: 10.1016/j.bmcl.2012.08.086. Epub 2012 Aug 30. Bioorg Med Chem Lett. 2012. PMID: 22995624
Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma.
Takano K, Munehira Y, Hatanaka M, Murakami R, Shibata Y, Shida T, Takeuchi K, Takechi S, Tabata T, Shimada T, Kishikawa S, Matsui Y, Ubukata O, Seki T, Kaneta Y. Takano K, et al. Among authors: seki t. Mol Cancer Ther. 2023 Mar 2;22(3):317-332. doi: 10.1158/1535-7163.MCT-22-0306. Mol Cancer Ther. 2023. PMID: 36622773
2,567 results